Summary

Eligibility
for people ages 18-65 (full criteria)
Location
at UCLA
Dates
study started
completion around
Principal Investigator
by Lara Ray, PhD (ucla)

Description

Summary

This study will randomize 64 non-treatment seeking individuals who smoke cigarettes daily in a double-blind, placebo-controlled laboratory study testing the effects of cytisinicline on the neural substrates of cigarette cue reactivity.

Official Title

Examining the Effects of Cytisinicline on Neural Substrates of Cigarette Cue-Reactivity

Details

The objective of this study is to examine the effects of cytisinicline on neural substrates of cigarette cue-reactivity. We will randomize 64 adults who smoke cigarettes daily (N=32 cytisinicline, N=32 placebo; 50% female) into a double-blind, placebo-controlled laboratory study of cytisinicline. Specifically, participants will complete a 2- to 3-week outpatient protocol that includes taking cytisinicline (3 mg, 3 times daily) or matched placebo (0 mg, 3 times daily) and completing a brief daily diary assessment of cigarette use and craving. Following 2- to 3-weeks of cytisinicline (or placebo) treatment, participants will complete a cigarette cue-exposure task during fMRI. Total study participation will be approximately 4 weeks.

Keywords

Smoking Cessation, Tobacco Use Disorder, smoking cesstion, cigarette smoking, fMRI, cytisinicline

Eligibility

Location

  • University of California Los Angeles accepting new patients
    Los Angeles California 90049 United States

Lead Scientist at University of California Health

  • Lara Ray, PhD (ucla)
    Professor, Psychology, College of Letters and Science. Authored (or co-authored) 276 research publications

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
University of California, Los Angeles
ID
NCT06617312
Phase
Phase 2 research study
Study Type
Interventional
Participants
Expecting 64 study participants
Last Updated